Duratia: Advanced Treatment for Premature Ejaculation
| Product dosage: 30mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.23 | $36.98 (0%) | 🛒 Add to cart |
| 60 | $1.10 | $73.96 $66.22 (10%) | 🛒 Add to cart |
| 90 | $0.97 | $110.94 $87.72 (21%) | 🛒 Add to cart |
| 120 | $0.90 | $147.92 $107.50 (27%) | 🛒 Add to cart |
| 180 | $0.82 | $221.88 $147.06 (34%) | 🛒 Add to cart |
| 270 | $0.73 | $332.82 $197.80 (41%) | 🛒 Add to cart |
| 360 | $0.60
Best per pill | $443.76 $216.72 (51%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.70 | $36.98 (0%) | 🛒 Add to cart |
| 20 | $3.27 | $73.96 $65.36 (12%) | 🛒 Add to cart |
| 30 | $3.12 | $110.94 $93.74 (16%) | 🛒 Add to cart |
| 60 | $1.43 | $221.88 $86.00 (61%) | 🛒 Add to cart |
| 90 | $1.22 | $332.82 $110.08 (67%) | 🛒 Add to cart |
| 120 | $1.10 | $443.76 $132.44 (70%) | 🛒 Add to cart |
| 180 | $0.98 | $665.64 $176.30 (74%) | 🛒 Add to cart |
| 270 | $0.90 | $998.46 $241.66 (76%) | 🛒 Add to cart |
| 360 | $0.85
Best per pill | $1331.28 $306.16 (77%) | 🛒 Add to cart |
| Product dosage: 90mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.45 | $49.02 (0%) | 🛒 Add to cart |
| 30 | $1.83 | $73.53 $55.04 (25%) | 🛒 Add to cart |
| 60 | $1.63 | $147.06 $98.04 (33%) | 🛒 Add to cart |
| 90 | $1.51 | $220.59 $135.88 (38%) | 🛒 Add to cart |
| 120 | $1.43 | $294.12 $171.14 (42%) | 🛒 Add to cart |
| 180 | $1.34 | $441.18 $241.66 (45%) | 🛒 Add to cart |
| 270 | $1.30 | $661.77 $350.02 (47%) | 🛒 Add to cart |
| 360 | $1.26
Best per pill | $882.36 $452.36 (49%) | 🛒 Add to cart |
Duratia is a prescription medication containing dapoxetine, specifically formulated for the management of premature ejaculation (PE) in adult men. As a selective serotonin reuptake inhibitor (SSRI) with a rapid onset and short half-life, Duratia is the first oral agent approved for on-demand use to improve ejaculatory control, increase intravaginal ejaculatory latency time (IELT), and enhance sexual satisfaction for both patients and their partners. Its targeted mechanism and evidence-based efficacy make it a cornerstone in modern sexual medicine for addressing this common yet impactful condition.
Features
- Active ingredient: Dapoxetine hydrochloride
- Available strengths: 30 mg and 60 mg film-coated tablets
- Rapid absorption: Peak plasma concentration reached within 1–2 hours
- Short elimination half-life: Approximately 15 hours
- On-demand dosing: Designed for use 1–3 hours prior to anticipated sexual activity
- High selectivity for serotonin transporter (SERT) with minimal affinity for other receptors
Benefits
- Significantly increases time to ejaculation, improving sexual endurance
- Enhances perceived control over ejaculation, reducing anxiety related to sexual performance
- Improves sexual satisfaction for both the individual and their partner
- On-demand dosing offers flexibility without requiring daily medication commitment
- Evidence-based improvement in patient-reported outcomes and quality of life measures
- Well-tolerated profile with side effects generally diminishing after initial doses
Common use
Duratia is indicated for the treatment of premature ejaculation in adult men aged 18–64 years. It is prescribed for patients who meet the diagnostic criteria for lifelong or acquired PE, characterized by persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the person wishes it, causing marked distress or interpersonal difficulty. The medication is intended for on-demand use in sexually active men and should be administered only when sexual activity is anticipated.
Dosage and direction
The recommended starting dose is 30 mg taken orally 1–3 hours before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 60 mg. Duratia should not be taken more than once every 24 hours. Tablets should be swallowed whole with at least one full glass of water, with or without food. Patients should avoid consuming alcohol while taking Duratia due to increased risk of adverse events. Dose adjustment is recommended in patients with renal or hepatic impairment.
Precautions
Patients should be evaluated for underlying medical or psychiatric conditions that may contribute to ejaculatory dysfunction. Caution is advised in patients with history of syncope, orthostatic hypotension, or cardiovascular disease. Duratia may cause dizziness or syncope; patients should avoid driving or operating machinery until they know how the medication affects them. Use with caution in patients with bleeding tendencies or those taking anticoagulants. Not recommended for use in men with cardiac conduction abnormalities or uncontrolled hypertension.
Contraindications
Duratia is contraindicated in patients with known hypersensitivity to dapoxetine or any excipients in the formulation. It should not be used in combination with monoamine oxidase inhibitors (MAOIs), thioridazine, or other SSRIs due to risk of serotonin syndrome. Contraindicated in patients with significant hepatic impairment, unstable epilepsy, or history of mania/hypomania. Not recommended for use in patients with severe renal impairment (CrCl <30 mL/min). Concurrent use with potent CYP3A4 inhibitors is contraindicated.
Possible side effects
Common adverse reactions (≥1%) include nausea (11.0%), dizziness (5.8%), headache (5.6%), diarrhea (3.9%), insomnia (3.1%), and fatigue (2.1%). Less frequently reported effects include orthostatic hypotension, syncope, blurred vision, tinnitus, and anxiety. Most side effects are mild to moderate in severity and tend to decrease with continued use. Serious but rare adverse events include serotonin syndrome, syncope with associated injury, and priapism. Patients should report any persistent or severe side effects to their healthcare provider.
Drug interaction
Duratia is primarily metabolized by CYP3A4, CYP2D6, and flavin-containing monooxygenase systems. Concomitant use with potent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) is contraindicated. Moderate CYP3A4 inhibitors may increase dapoxetine exposure. Concurrent use with other serotonergic drugs (tramadol, triptans, other SSRIs) increases risk of serotonin syndrome. May potentiate effects of alcohol and other CNS depressants. Use with alpha-adrenergic blockers may increase risk of orthostatic hypotension. Caution with anticoagulants due to potential increased bleeding risk.
Missed dose
As Duratia is taken on an as-needed basis rather than on a scheduled regimen, the concept of a “missed dose” does not apply. Patients should take one tablet approximately 1–3 hours before anticipated sexual activity. If sexual activity does not occur after taking Duratia, no additional dose should be taken until before the next anticipated sexual activity, with at least 24 hours between doses.
Overdose
Symptoms of overdose may include serotonin syndrome (agitation, confusion, diaphoresis, tachycardia, hyperthermia), syncope, dizziness, nausea, and vomiting. There is no specific antidote for dapoxetine overdose. Treatment should consist of general supportive measures, including monitoring of vital signs and ECG. Gastric lavage may be considered if performed soon after ingestion. Administration of activated charcoal may be useful. Management of serotonin syndrome may require benzodiazepines, cyproheptadine, and supportive care.
Storage
Store at room temperature (15–30°C or 59–86°F) in the original container to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers, as the original packaging provides protection from humidity. Discard any tablets that appear discolored, damaged, or show signs of deterioration.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Duratia is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary. Patients should consult their healthcare provider for proper diagnosis and treatment recommendations. Never share medication with others, even if they exhibit similar symptoms.
Reviews
Clinical studies demonstrate that Duratia significantly improves IELT and patient-reported outcomes measures. In randomized controlled trials, mean IELT increased from approximately 0.9 minutes at baseline to 3.1 minutes with Duratia 30 mg and 3.6 minutes with Duratia 60 mg. Patient Global Impression of Change (PGI-C) scores showed 68% of patients reported much or very much improvement compared to 20% with placebo. Partner satisfaction scores similarly improved significantly. Real-world evidence supports maintained efficacy and tolerability with appropriate patient selection and dosing.